Have you or someone you know been diagnosed with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)?

Consider enrolling in the TakeAim Leukemia trial - a clinical research study evaluating emavusertib alone or in combination with azacitidine or venetoclax. The study is evaluating the effects of these treatment on Higher-Risk Myelodysplastic Syndrome (hrMDS) or Acute Myeloid Leukemia (AML).

Emavusertib is an investigational drug that is not approved by the FDA or other global health authorities in AML or MDS. Safety and efficacy have not been established.

Contact your doctor to discuss participating in this clinical trial. For more information about emavusertib (CA-4948) visit ClinicalTrials.gov and search (NCT04278768).